Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Research article

Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients

Authors: Panagiotis Pateinakis, Aikaterini Papagianni, Stella Douma, Georgios Efstratiadis, Dimitrios Memmos

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Cardiovascular morbidity and mortality remains excessive in patients with chronic kidney disease. The association of vascular changes with regulators of extraosseous calcification in this patient population is still under investigation. The aim of the present study was to investigate the associations of the calcification inhibitor fetuin-A, and the anti-osteoclastic factor osteoprotegerin (OPG) with vascular pathology in chronic hemodialysis patients.

Methods

In this cross-sectional study including 81 stable chronic hemodialysis patients, we measured carotid-to-femoral pulse wave velocity (cfPWV) with applanation tonometry, reflecting arterial stiffness, and common carotid intima-media thickness (ccIMT), a surrogate of early atherosclerosis, as well as serum levels of fetuin-A and OPG. Co-morbidities, traditional cardiovascular risk factors, inflammatory markers and mineral-bone disease serology parameters were also recorded.

Results

cfPWV correlated inversely with fetuin-A (r=−0.355, p=0.001) and positively with OPG (r=0.584, p<0.001). In multilinear regression analysis including age, gender, diabetes, cardiovascular disease, hypertension, pulse pressure, LDL, logCRP, both fetuin-A and OPG were independently associated with cfPWV (p=0.024 and p=0.041 respectively). ccIMT was negatively associated with fetuin-A (r=−0.312, p=0.005) and positively with OPG (r=0.521, p<0.0001); however these associations lost statistical significance after adjustment for age.

Conclusion

In chronic hemodialysis patients both fetuin-A and OPG levels are independently associated with arterial stiffness but not with early atherosclerotic vascular changes.
Appendix
Available only for authorised users
Literature
1.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006, 17: 2034-2047. 10.1681/ASN.2005101085.CrossRefPubMed
2.
Amann K: Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol. 2008, 3: 1599-1605. 10.2215/CJN.02120508.CrossRefPubMed
3.
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003, 18: 1731-1740. 10.1093/ndt/gfg414.CrossRefPubMed
4.
London GM, Marchais SJ, Guerin AP: Arterial stiffness and function in end-stage renal disease. Adv Chronic Kidney Dis. 2004, 11: 202-209. 10.1053/j.arrt.2004.02.008.CrossRefPubMed
5.
Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008, 19: 213-216. 10.1681/ASN.2007080854.CrossRefPubMed
6.
Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003, 112: 357-366.CrossRefPubMedPubMedCentral
7.
Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005, 16: 2920-2930. 10.1681/ASN.2004100895.CrossRefPubMed
8.
Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003, 361: 827-833. 10.1016/S0140-6736(03)12710-9.CrossRefPubMed
9.
Aoki A, Murata M, Asano T, Ikoma A, Sasaki M, Saito T, Otani T, Jinbo S, Ikeda N, Kawakami M, Ishikawa SE: Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. Cardiovas Diabetol. 2013, 12: 11-10.1186/1475-2840-12-11.CrossRef
10.
Speer G, Fekete BC, El Hadj Othmane T, Szabo T, Egresits J, Fodor E, Kiss I, Logan AG, Nemcsik J, Szabo A, Nemeth ZK, Szathmari M, Tisler A: Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant. 2008, 23: 3256-3262. 10.1093/ndt/gfn242.CrossRefPubMed
11.
Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM: Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006, 17: 262-270. 10.1681/ASN.2006080924.CrossRefPubMed
12.
Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L: The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant. 2008, 23: 3263-3271. 10.1093/ndt/gfn226.CrossRefPubMed
13.
Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006, 27: 2588-2605. 10.1093/eurheartj/ehl254.CrossRefPubMed
14.
Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Jaff M, Kownator S, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS, Zannad F, Zureik M: Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovas Dis. 2007, 23: 75-80. 10.1159/000097034.CrossRef
15.
Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Shepp SG, Roccella EJ: Recommendations for blood pressure measurement in human and experimental animals; part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005, 111: 697-716. 10.1161/01.CIR.0000154900.76284.F6.CrossRefPubMed
16.
Covic A, Kanbay M, Voroneanu L, Turgut F, Serban DN, Serban IL, Goldsmith DJ: Vascular calcification in chronic kidney disease. Clin Sci (Lond). 2010, 119: 111-121. 10.1042/CS20090631.CrossRef
17.
Osorio A, Ortega E, Torres JM, Sanchez P, Ruiz-Requena E: Biochemical markers of vascular calcification in elderly hemodialysis patients. Mol Cell Biochem. 2013, 374: 21-27. 10.1007/s11010-012-1500-y.CrossRefPubMed
18.
Lee CT, Chua S, Hsu CY, Tsai YC, Ng HY, Kuo CC, Wu CH, Chen TC, Chiu TT, Lee YT: Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis Markers. 2013, 34: 229-235. 10.1155/2013/846059.CrossRefPubMedPubMedCentral
19.
Ix JH, Barrett-Connor E, Wassel CL, Cummins K, Bergstrom J, Daniels LB, Laughlin GA: The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: the Rancho Bernardo Study. J Am Coll Cardiol. 2011, 58: 2372-2379. 10.1016/j.jacc.2011.08.035.CrossRefPubMedPubMedCentral
20.
Pencak P, Czerwienska B, Ficek R, Wyskida K, Kujawa-Szewieczek A, Olszanecka-Glinianowicz M, Wiecek A, Chudek J: Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients. BMC Nephrol. 2013, 14: 10-10.1186/1471-2369-14-10.CrossRefPubMedPubMedCentral
21.
Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E, Motoyama K, Koyama H, Shoji T, Inaba M, Nishizawa Y: Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf). 2007, 66: 246-250. 10.1111/j.1365-2265.2006.02716.x.CrossRef
22.
Roos M, Richart T, Kouznetsova T, von Eynatten M, Lutz J, Heemann U, Baumann M, Staessen JA: Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept. 2009, 154: 39-43. 10.1016/j.regpep.2008.12.001.CrossRefPubMed
23.
Schlieper G, Brandenburg V, Djuric Z, Damjanovic T, Markovic N, Westenfeld R, Dimkovic N, Ketteler M, Floege J: Is there a correlation between C-reactive protein and calcification inhibitors with cardiovascular parameters and risk factors in hemodialysis patients. Dtsch Med Wochenschr. 2007, 132: 1820-1824. 10.1055/s-2007-984969.CrossRefPubMed
24.
Porazko T, Kuzniar J, Kusztal M, Kuzniar TJ, Weyde W, Kuriata-Kordek M, Klinger M: Increased aortic wall stiffness associated with low circulating fetuin A and high C-reactive protein in predialysis patients. Nephron Clin Pract. 2009, 113: c81-c87. 10.1159/000228539.CrossRefPubMed
25.
Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Gladziwa U, Rensma PL, Bartelet K, Konings CJ, Hoeks AP, Floege J, Leunissen KM: Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant. 2006, 21: 1293-1299. 10.1093/ndt/gfk045.CrossRefPubMed
26.
Guarneri M, Geraci C, Incalcaterra F, Arsena R, Mule G, Vaccaro F, Luna C, Cerasola G, Cottone S: Subclinical atherosclerosis and fetuin-A plasma levels in essential hypertensive patients. Hypertens Res. 2013, 36: 129-133. 10.1038/hr.2012.136.CrossRefPubMed
27.
Fiore CE, Celotta G, Politi GG, Di Pino L, Castelli Z, Mangiafico RA, Signorelli SS, Pennisi P: Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis. 2007, 195: 110-115. 10.1016/j.atherosclerosis.2006.08.052.CrossRefPubMed
28.
Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B: Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract. 2008, 108: c233-c240. 10.1159/000120209.CrossRefPubMed
29.
Ziolkowska H, Brzewski M, Roszkowska-Blaim M: Determinants of the intima-media thickness in children and adolescents with chronic kidney disease. Pediatr Nephrol. 2008, 23: 805-811. 10.1007/s00467-007-0733-6.CrossRefPubMed
30.
Hermans MM, Kooman JP, Brandenburg V, Ketteler M, Damoiseaux JG, Tervaert JW, Ferreira I, Rensma PL, Gladziwa U, Kroon AA, Hoeks AP, Stehouwer CD, Leunissen KM: Spatial inhomogeneity of common carotid artery intima-media is increased in dialysis patients. Nephrol Dial Transplant. 2007, 22: 1205-1212. 10.1093/ndt/gfl750.CrossRefPubMed
31.
Pertosa G, Simone S, Ciccone M, Porreca S, Zaza G, Dalfino G, Memoli B, Procino A, Bonomini M, Sirolli V, Castellano G, Gesualdo L, Ktena M, Schena FP, Grandaliano G: Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis?. Am J Kidney Dis. 2009, 53: 467-474. 10.1053/j.ajkd.2008.10.046.CrossRefPubMed
32.
Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Eyileten T, Sonmez A, Oguz Y, Oner K, Ors F, Vural A, Yenicesu M: Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation. 2007, 83: 392-397. 10.1097/01.tp.0000251647.72673.c7.CrossRefPubMed
33.
Chen HY, Chiu YL, Chuang YF, Hsu SP, Pai MF, Lai CF, Yang JY, Peng YS, Tsai TJ, Wu KD: Association of low serum fetuin A levels with poor arteriovenous access patency in patients undergoing maintenance hemodialysis. Am J Kidney Dis. 2010, 56: 720-727. 10.1053/j.ajkd.2010.06.015.CrossRefPubMed
34.
Chen HY, Chiu YL, Hsu SP, Pai MF, Yang JY, Peng YS: Low serum fetuin A levels and incident stroke in patients with maintenance haemodialysis. Eur J Clin Invest. 2013, 43: 387-396. 10.1111/eci.12057.CrossRefPubMed
35.
Cozzolino M, Galassi A, Biondi ML, Turri O, Papagni S, Mongelli N, Civita L, Gallieni M, Brancaccio D: Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol. 2006, 26: 423-429. 10.1159/000095782.CrossRefPubMed
36.
Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU: Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006, 29: 853-857. 10.2337/diacare.29.04.06.dc05-1938.CrossRefPubMed
37.
Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006, 113: 1760-1767. 10.1161/CIRCULATIONAHA.105.588723.CrossRefPubMedPubMedCentral
38.
Jensen MK, Bartz TM, Mukamal KJ, Djousse L, Kizer JR, Tracy RP, Zieman SJ, Rimm EB, Siscovick DS, Shlipak M, Ix JH: Fetuin-A, Type 2 Diabetes, and Risk of Cardiovascular Disease in Older Adults: The Cardiovascular Health Study. Diabetes Care. 2013, 36: 1222-1228. 10.2337/dc12-1591.CrossRefPubMedPubMedCentral
39.
Patidar A, Singh DK, Winocour P, Farrington K, Baydoun AR: Human uraemic serum displays calcific potential in vitro that increases with advancing chronic kidney disease. Clin Sci (Lond). in press
40.
Morena M, Jaussent I, Halkovich A, Dupuy AM, Bargnoux AS, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B, Cristol JP: Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS One. 2012, 7 (5): e36175-10.1371/journal.pone.0036175.CrossRefPubMedPubMedCentral
41.
Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, Unsal A, Yildiz A: Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol. 2012, 7: 965-973. 10.2215/CJN.11191111.CrossRefPubMedPubMedCentral
42.
Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000, 192: 463-474. 10.1084/jem.192.4.463.CrossRefPubMedPubMedCentral
43.
Price PA, June HH, Buckley JR, Williamson MK: Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001, 21: 1610-1616. 10.1161/hq1001.097102.CrossRefPubMed
44.
Scialla JJ, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, Hanish A, Raj D, Rosas SE, Seliger SL, Weir MR, Parekh RS, CRIC Study Group: Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011, 6: 2612-2619. 10.2215/CJN.03910411.CrossRefPubMedPubMedCentral
45.
Nakashima A, Carrero JJ, Qureshi AR, Hirai T, Takasugi N, Ueno T, Taniguchi Y, Lindholm B, Yorioka N: Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int. 2011, 22: 1695-1701. 10.1007/s00198-010-1377-0.CrossRefPubMed
46.
Erdogan B, Aslan E, Bagis T, Gokcel A, Erkanli S, Bavbek M, Altinors N: Intima-media thickness of the carotid arteries is related to serum osteoprotegerin levels in healthy postmenopausal women. Neurol Res. 2004, 26: 658-661. 10.1179/016164104225014157.CrossRefPubMed
47.
Akinci B, Demir T, Celtik A, Baris M, Yener S, Ozcan MA, Yuksel F, Secil M, Yesil S: Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes. Diabetes Res Clin Pract. 2008, 82: 172-178. 10.1016/j.diabres.2008.07.014.CrossRefPubMed
48.
Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB: Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromso Study. J Thromb Haemost. 2010, 8: 2133-2139. 10.1111/j.1538-7836.2010.03990.x.CrossRefPubMed
49.
Rozas Moreno P, Reyes Garcia R, Garcia-Martin A, Varsavsky M, Garcia-Salcedo JA, Munoz-Torres M: Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?. J Endocrinol Invest. 2013, 36: 16-20.PubMed
50.
Ciccone MM, Scicchitano P, Gesualdo M, Zito A, Carbonara R, Locorotondo M, Mandurino C, Masi F, Boccalini F, Lepera ME: Serum osteoprotegerin and carotid intima-media thickness in acute/chronic coronary artery diseases. J Cardiovasc Med (Hagerstown). 2013, 14: 43-48. 10.2459/JCM.0b013e3283561433.CrossRef
51.
Janda K, Krzanowski M, Chowaniec E, Kusnierz-Cabala B, Dumnicka P, Krasniak A, Podolec P, Sulowicz W: Osteoprotegerin as a marker of cardiovascular risk in peritoneal dialysis patients. Pol Arch Med Wewn. in press
Metadata
Title
Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients
Authors
Panagiotis Pateinakis
Aikaterini Papagianni
Stella Douma
Georgios Efstratiadis
Dimitrios Memmos
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-122

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue

Research article

Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis

Research article

An in vitroassessment of panel of engineered nanomaterials using a human renal cell line: cytotoxicity, pro-inflammatory response, oxidative stress and genotoxicity

Case report

An unusual case of glomerulonephritis in a patient with non-Hodgkin Mucosal Associated Lymphoid Tissue (MALT) B-cell lymphoma

Research article

Renal function, calcium regulation, and time to hospitalization of patients with chronic kidney disease

Research article

Ethnic differences in the association between blood pressure components and chronic kidney disease in middle aged and older Asian adults

Research article

Estimation of glomerular filtration rate by a radial basis function neural network in patients with type-2 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits